GM
CRSP icon

Gilfoyle Management’s CRISPR Therapeutics CRSP Stock Holding History

Gilfoyle Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$6.38K Buy
150
+50
+50% +$2.58K 12.96% 3
2023
Q2 		$4.84K Buy
+100
New +$5.67K 25% 1

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gilfoyle Management's CRSP Position: Q3 2023 in Review

Gilfoyle Management increased its CRISPR Therapeutics (CRSP) stake by 50% in Q3 2023, buying an estimated $2.58K and bringing the position to 150 shares worth $6.38K. The position accounts for 12.96% of the portfolio, ranked #3.

Gilfoyle Management first reported a position in CRSP in Q2 2023 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

  • Gilfoyle Management held 150 shares of CRISPR Therapeutics worth $6.38K as of Q3 2023.
  • Gilfoyle Management bought 50 CRISPR Therapeutics shares in Q3 2023, an estimated $2.58K.
  • CRISPR Therapeutics made up 12.96% of Gilfoyle Management's portfolio in Q3 2023, its #3 holding.
  • Gilfoyle Management first reported a position in CRISPR Therapeutics in Q2 2023 and has held it in 2 quarters since.
  • 405 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on Gilfoyle Management's 13F filing for Q3 2023, filed 10 Oct 2023.